Here, for the first time, the peptide TRPV1 blocker, HCRG21, was used to treat chronic inflammatory skin conditions, psoriasis, and ACD using IMQ- and DNFB-induced CD-1 mouse models, respectively. This evidence concerns the gene TRPV1 and granular corneal dystrophy type II.